• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Heptares Therapeutics - Articles and news items

HTL1071

Initiation of HTL1071 trial triggers $10m payment to Heptares

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

The first subject has been dosed with immuno-oncology candidate HTL1071 in a Phase I clinical study, triggering a US$10 million payment to Heptares…

HTL9936

Positive Phase 1b results for Heptares’ HTL9936

Industry news / 10 February 2016 / Victoria White

HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia…

HTL9936

Heptares announces positive outcome of Phase 1a study of HTL9936

Industry news / 17 June 2015 / Victoria White

Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, has announced the positive outcome of its Phase 1a study with HTL9936…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +